国际眼科 >> 幻灯

[ARVO2012]IVAN研究1年结果
国际眼科时讯网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

玻璃体视网膜 多学科交叉   2012/5/8 15:48:24  点击数:1514    加入收藏 
 关键字:ARVO IVAN 

内容概要:  One year after randomization, the comparison between bevacizumab andranibizumab was inconclusive (bevacizumab minus ranibizumab -1.99 letters, 95%confidence interval (CI) -4.04 to 0.06). Discontinuous treatment was equivalent to continuoustreatment (discontinuous minus continuous -0.35 letters, 95% CI -2.40 to 1.70).

用户评论

查看全部评论
用户:Gracelyn 时间:2017/3/12 21:10:27
Woot, I will celarinty put this to good use!

用户:Justis 时间:2017/3/15 11:19:30
Felt so hopeless looking for answers to my quteoisns...until now.

 
作者:
评论标题:
评论内容:  
/ 4000                   
* 网友评论仅供其表达个人看法,并不表明国际循环网同意其观点或证实其描述。